Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: A study of the perugia multidisciplinary team for thoracic oncology

Journal of Thoracic Oncology

Volumn 3, Issue 4, 2008, Pages 365-373

  Ludovini, Vienna ^a,e   Pistola, Lorenza ^a   Gregorc, Vanesa ^b   Floriani, Irene ^c   Rulli, Eliana ^c   Piattoni, Simonetta ^d   Di Carlo, Luciana ^d   Semeraro, Antonia ^d   Darwish, Samir ^a   Tofanetti, Francesca Romana ^a   Stocchi, Lucia ^a   Mihaylova, Zhasmina ^a   Bellezza, Guido ^d   Del Sordo, Rachele ^d   Daddi, Giuliano ^d   Crinò, Lucio ^a   Tonato, Maurizio ^a  

^a Azienda Ospedaliera   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Microsatellite alterations; Non small cell lung cancer; p53; Prognosis; Quantification plasma DNA

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CHROMOSOME 3P; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE ALTERATION; MUTATION; PLASMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; SQUAMOUS CELL; STATISTICAL SIGNIFICANCE;

EID: 41749114329     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318168c7d0     Document Type: Article

References (35)

1. Hunter T. Cooperation between oncogenes (Review). Cell 1991;64:249-270.
2. Nowell PC. The clonal evolution of tumor cell populations. Science (Washington DC) 1976;194:23-28.
3. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. (Review) Cell 1990;61:757-767. Comment in: Cell 2004;118:671-674.
4. Virmani AK, Fong KM, Kodagoda D, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-319.
5. Froudarakis, ME, Sourvinos G, Fournel P, et al. Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small cell lung cancer. Chest 1998;113:1091-1094.
6. Sanchez-Cespedes M, Rosell R, Pifarre A, et al. Microsatellite alterations at 5q21, 11p13, and 11p15. 5 do not predict survival in non-small cell lung cancer. Clinical Cancer Res 1997;3:1229-1235.
7. Rosell R, Pifarre A, Monzo M, et al. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 1997;74:330-334.
8. Fong KM, Zimmerman PV, Smith PJ. Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer. Genes Chromosomes Cancer 1994;10:183-189.
9. Pifarre A, Rosell R, Monzo M, et al. Microsatellite alterations in NSCLC. Prognostic value of replication errors on chromosomes 2p and 3p in non-small cell lung cancer. Br J Cancer 1997;75:184-189.
10. Field JK, Neville EM, Stewart MP, et al. Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. Br J Cancer 1996;74:1968-1974.
11. Shiseki M, Kohno T, Adachi J, et al. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 1996;17:71-77.
12. Sundaresan V, Chung G, Heppell-Parton A, et al. Homozygous delations at 3p12 in breast and lung cancer. Oncogene 1998;17:1723-1729.
13. Brentnall TA, Chen R, Lee JG, Kimmey MB, et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinomi and pancreatitis. Cancer Res 1995;55:4264-4267.
14. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:815-815.
15. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
16. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology (Basel) 1989;46:318-322.
17. Steinman CR. Free DNA in serum and plasma from normal adults. J Clin Invest 1980;66:1391-1399.
18. Shapiro B, Chakrabaty M, Cohn E, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983;51:2116-2120.
19. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. (Review) Semin Roentgenol 2005;40:90-97.
20. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
21. Heid CA, Stevens J, Livak K, et al. Real Time quantitative PCR. Genome Res 1996;6:986-994.
22. Holland PM, Abramson RD, Watson R, et al. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus acquaticus DNA polymerase. Proc Natl Acad Sci USA 1991;88:7276-7280.
23. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst (Bethesda) 1997;89:1366-1373.
24. Chung GT, Sundaresan V, Hasleton P, et al. Sequential molecular genetic changes in lung cancer development. Oncogene 1995;11:2591-2598.
25. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995;273:1908.
26. Burke L, Khan MA, Freedman AN, et al. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 1998;58:2533-2536.
27. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
28. Mitsudomi T, Oyama T, Nishida K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clinical Cancer Res 1996;2:1185-1189.
29. Nelson HH, Wiencke JK, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-1807.
30. Thiberville L, Bourguignon J, Metayer J, et al. Frequency and prognostic evaluation of 3p21-22 allelic losses in non small-cell lung cancer. Int J Cancer 1995;64:371-377.
31. Fong KM, Kida Y, Zimmerman PV, et al. Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 1995;55:4268-4272.
32. Gregorc V, Darwish S, Ludovini V, et al. The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer. Lung Cancer 2003;42:275-281.
33. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. (Review) Lung Cancer 1997;17:S37-S58.
34. Zienolddiny S, Ryberg D, Arab MO, et al. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 2001;84:226-231.
35. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678.